Published in J Cell Mol Med on February 04, 2008
Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal (2011) 1.17
Semaphorin 3A suppresses tumor growth and metastasis in mice melanoma model. PLoS One (2012) 1.05
Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. Radiat Oncol (2010) 1.01
Osteopontin regulates human glioma cell invasiveness and tumor growth in mice. Neuro Oncol (2009) 1.00
Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer. J Exp Clin Cancer Res (2012) 0.95
Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma. Immunology (2010) 0.95
Adenosine and osteopontin contribute to the development of chronic obstructive pulmonary disease. FASEB J (2009) 0.92
Functional characterization of stromal osteopontin in melanoma progression and metastasis. PLoS One (2013) 0.79
Aerosol delivery of small hairpin osteopontin blocks pulmonary metastasis of breast cancer in mice. PLoS One (2010) 0.77
Osteopontin regulates proliferation, apoptosis, and migration of murine claudin-low mammary tumor cells. BMC Cancer (2016) 0.75
Osteopontin and oral carcinogenesis. J Cell Mol Med (2008) 0.75
Osteopontin at the Crossroads of Inflammation and Tumor Progression. Mediators Inflamm (2017) 0.75
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov (2007) 11.46
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med (2005) 4.11
Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol (2006) 3.48
A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res (2004) 2.72
Induction of plasma cell tumours in BALB-c mice with 2,6,10,14-tetramethylpentadecane (pristane). Nature (1969) 1.82
Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res (2008) 1.78
Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem (2001) 1.74
An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene (2006) 1.61
SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res (2003) 1.55
Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem (2002) 1.49
Meeting report: summary of IARC monographs on formaldehyde, 2-butoxyethanol, and 1-tert-butoxy-2-propanol. Environ Health Perspect (2005) 1.49
NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia (2003) 1.47
The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med (2006) 1.42
Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo. Clin Cancer Res (2007) 1.31
Cancer biomarkers: knowing the present and predicting the future. Future Oncol (2005) 1.29
Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression. Mol Carcinog (2005) 1.28
The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia (2001) 1.24
Swelling-activated, cystic fibrosis transmembrane conductance regulator-augmented ATP release and Cl- conductances in murine C127 cells. J Physiol (2000) 1.23
Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clin Exp Metastasis (2003) 1.18
Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12. Oncogene (2005) 1.16
Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Curr Cancer Drug Targets (2004) 1.16
Endogenous RNA tumor viruses are activated during chemical induction of murine plasmacytomas. Proc Natl Acad Sci U S A (1978) 1.09
Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J Bone Miner Res (2001) 1.08
Papilloma development is delayed in osteopontin-null mice: implicating an antiapoptosis role for osteopontin. Cancer Res (2006) 1.07
Prostaglandin E2 receptors EP2 and EP4 are up-regulated in peritoneal macrophages and joints of pristane-treated mice and modulate TNF-alpha and IL-6 production. J Leukoc Biol (2004) 1.04
Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo. Cancer Gene Ther (2006) 1.02
Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther (2004) 1.00
Osteopontin: an emerging therapeutic target for anticancer therapy. Expert Opin Ther Targets (2007) 0.99
Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis. J Biol Chem (2006) 0.97
Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett (2003) 0.95
The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alpha/c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis. Cancer Res (2006) 0.93
Osteopontin is strongly expressed by alveolar macrophages in the lungs of acute respiratory distress syndrome. Lung (2004) 0.91
Osteopontin-deficiency suppresses growth of B16 melanoma cells implanted in bone and osteoclastogenesis in co-cultures. J Bone Miner Res (2004) 0.87
Comparison of the promoting activity of pristane and n-alkanes in skin carcinogenesis with their physical effects on micellar models of biological membranes. Biochim Biophys Acta (1981) 0.87
Identification of promoter regions involved in cell- and developmental stage-specific osteopontin expression in bone, kidney, placenta, and mammary gland: an analysis of transgenic mice. J Bone Miner Res (2004) 0.86
Override of the osteoclast defect in osteopontin-deficient mice by metastatic tumor growth in the bone. Am J Pathol (2006) 0.85
Anti-invasive/anti-metastasis strategies: new roads, new tools and new hopes. Curr Cancer Drug Targets (2006) 0.84
Targeting metastatic and advanced breast cancer. Semin Oncol Nurs (2007) 0.83
Translocation and activation of protein kinase C by the plasma cell tumor-promoting alkane pristane. Cancer Res (1995) 0.82
Inhibitory effect of antisense epidermal growth factor receptor RNA on the proliferation of rat C6 glioma cells in vitro and in vivo. J Neurosurg (2000) 0.80
Analysis of transcriptional activation of a cyclic AMP response element by 2,6,10,14-tetramethylpentadecane (pristane) in JB6 mouse epidermal cells. Mol Carcinog (1994) 0.79
Insulin-like growth factor-I produced by seminal vesicles: relationship to intraepithelial basal cell hyperplasia in the prostate. Clin Cancer Res (2007) 0.79
An extrachromosomal tetracycline-regulatable system for mammalian cells. Nucleic Acids Res (2000) 0.78
[RNA interference and its possible use in cancer therapy]. Bull Cancer (2004) 0.77
Immunoscintigraphy of MCF7 rat mammary tumour xenograft using monoclonal antibody. Indian J Biochem Biophys (1994) 0.76
[Chromosome translocations and the activation of C-myc oncogene in mouse plasmacytomas]. Gan To Kagaku Ryoho (1984) 0.76
Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol (2006) 3.48
Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase. J Biol Chem (2003) 2.05
Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition (2006) 1.92
Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res (2008) 1.78
A novel experimental strategy to assess the metabolic effects of selective activation of a G(q)-coupled receptor in hepatocytes in vivo. Endocrinology (2013) 1.62
Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. J Biol Chem (2004) 1.56
Probiotics in diverticular disease of the colon: an open label study. J Gastrointestin Liver Dis (2010) 1.50
Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem (2002) 1.49
The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med (2006) 1.42
Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem (2003) 1.34
Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res (2008) 1.31
Probiotics, their health benefits and applications for developing healthier foods: a review. FEMS Microbiol Lett (2012) 1.24
Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev Res (Phila) (2009) 1.22
Cancer-preventing attributes of probiotics: an update. Int J Food Sci Nutr (2010) 1.20
Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res (2012) 1.17
Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J Biol Chem (2004) 1.13
Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets (2011) 1.11
Matrix metalloproteinase-2: mechanism and regulation of NF-kappaB-mediated activation and its role in cell motility and ECM-invasion. Glycoconj J (2004) 1.09
Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression. IUBMB Life (2005) 1.09
Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-kappaB dependent AP-1-mediated ICAM-1 expression in breast cancer cells. Mol Cancer (2010) 1.08
Oral administration of dahi containing probiotic Lactobacillus acidophilus and Lactobacillus casei delayed the progression of streptozotocin-induced diabetes in rats. J Dairy Res (2008) 1.06
Semaphorin 3A suppresses tumor growth and metastasis in mice melanoma model. PLoS One (2012) 1.05
Novel designer receptors to probe GPCR signaling and physiology. Trends Pharmacol Sci (2013) 1.03
Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells. Carcinogenesis (2009) 1.02
Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells. Mol Cancer (2010) 1.01
Osteopontin: an emerging therapeutic target for anticancer therapy. Expert Opin Ther Targets (2007) 0.99
Hyaluronan-binding protein 1 (HABP1/p32/gC1qR) induces melanoma cell migration and tumor growth by NF-kappa B dependent MMP-2 activation through integrin α(v)β(3) interaction. Cell Signal (2011) 0.99
Osteopontin as a therapeutic target for cancer. Expert Opin Ther Targets (2014) 0.99
Osteopontin stimulates melanoma growth and lung metastasis through NIK/MEKK1-dependent MMP-9 activation pathways. Oncol Rep (2007) 0.97
Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis. J Biol Chem (2006) 0.97
Retracted JNK1 differentially regulates osteopontin-induced nuclear factor-inducing kinase/MEKK1-dependent activating protein-1-mediated promatrix metalloproteinase-9 activation. J Biol Chem (2005) 0.97
Biological and medicinal properties of grapes and their bioactive constituents: an update. J Med Food (2009) 0.95
Nuclear factor inducing kinase: a key regulator in osteopontin- induced MAPK/IkappaB kinase dependent NF-kappaB-mediated promatrix metalloproteinase-9 activation. Glycoconj J (2006) 0.94
Biological synthesis of silver nanoparticles using the fungus Humicola sp. and evaluation of their cytoxicity using normal and cancer cell lines. Spectrochim Acta A Mol Biomol Spectrosc (2013) 0.94
Molecular approaches for identification and characterization of lactic acid bacteria. J Dig Dis (2008) 0.93
Needle-based fluorescence endomicroscopy via structured illumination with a plastic, achromatic objective. J Biomed Opt (2013) 0.93
The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alpha/c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis. Cancer Res (2006) 0.93
p38 kinase is crucial for osteopontin-induced furin expression that supports cervical cancer progression. Cancer Res (2010) 0.93
Tyrosine kinase p56lck regulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through tyrosine phosphorylation of IkappaBalpha following hypoxia/reoxygenation. J Biol Chem (2003) 0.93
Bioactive peptides derived from milk proteins and their health beneficial potentials: an update. Food Funct (2010) 0.92
Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression. Mol Med Rep (2011) 0.92
Targeted cancer therapies: the future of cancer treatment. Acta Biomed (2012) 0.90
Exotic Fruits as Therapeutic Complements for Diabetes, Obesity and Metabolic Syndrome. Food Res Int (2011) 0.90
Alcohol, signaling, and ECM turnover. Alcohol Clin Exp Res (2009) 0.89
Internet resources for diabetes. Indian J Med Sci (2005) 0.88
Complementary and comparative study on hypoglycemic and antihyperglycemic activity of various extracts of Eugenia jambolana seed, Momordica charantia fruits, Gymnema sylvestre, and Trigonella foenum graecum seeds in rats. Appl Biochem Biotechnol (2009) 0.88
Medicinal and biological potential of pumpkin: an updated review. Nutr Res Rev (2010) 0.84
Preventive effect of diabegon, a polyherbal preparation, during progression of diabetes induced by high-fructose feeding in rats. J Pharmacol Sci (2007) 0.82
Biotechnological advancement in isolation of anti-neoplastic compounds from natural origin: a novel source of L-asparaginase. Acta Biomed (2010) 0.81
Functional foods in genomic medicine: a review of fermented papaya preparation research progress. Acta Biomed (2012) 0.80
Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkers. Oncol Lett (2013) 0.80
Effect of skim milk and dahi (yogurt) on blood glucose, insulin, and lipid profile in rats fed with high fructose diet. J Med Food (2006) 0.80
Functional characterization of stromal osteopontin in melanoma progression and metastasis. PLoS One (2013) 0.79
Diosgenin Functionalized Iron Oxide Nanoparticles as Novel Nanomaterial Against Breast Cancer. J Nanosci Nanotechnol (2015) 0.79
Effect of Dahi containing Lactococcus lactis on the progression of diabetes induced by a high-fructose diet in rats. Biosci Biotechnol Biochem (2006) 0.79
Regulating redox balance gene expression in healthy individuals by nutraceuticals: a pilot study. Rejuvenation Res (2010) 0.79
One-pot fluorescent labeling protocol for complex hydroxylated bioactive natural products. J Org Chem (2013) 0.79
Quercetin and sulforaphane in combination suppress the progression of melanoma through the down-regulation of matrix metalloproteinase-9. Exp Ther Med (2010) 0.79
Critical metabolic roles of β-cell M3 muscarinic acetylcholine receptors. Life Sci (2012) 0.78
Formation of oligosaccharides in skim milk fermented with mixed dahi cultures, Lactococcus lactis ssp diacetylactis and probiotic strains of lactobacilli. J Dairy Res (2007) 0.78
Protective effect of a phytocompound on oxidative stress and DNA fragmentation against paracetamol-induced liver damage. Ann Hepatol (2009) 0.78
Cardioprotective effect of a biofermented nutraceutical on endothelial function in healthy middle-aged subjects. Rejuvenation Res (2012) 0.78
Tyrosine kinase, p56lck-induced cell motility, and urokinase-type plasminogen activator secretion involve activation of epidermal growth factor receptor/extracellular signal regulated kinase pathways. J Biol Chem (2003) 0.78
Minireview: Novel aspects of M3 muscarinic receptor signaling in pancreatic β-cells. Mol Endocrinol (2013) 0.78
The effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei on gastropathic consequences in diabetic rats. J Med Food (2008) 0.77
Evaluation of micronuclei induction capacity and mutagenicity of organochlorine and organophosphate pesticides. Drug Metab Lett (2012) 0.77
Modified dipeptide-based nanoparticles: vehicles for targeted tumor drug delivery. Nanomedicine (Lond) (2013) 0.77
A sturgeon-derived bioactive compound beneficially modulates nuclear receptors controlling metabolic functions in patients with metabolic syndrome. Acta Biomed (2013) 0.77
Beneficial modulation from a high-purity caviar-derived homogenate on chronological skin aging. Rejuvenation Res (2012) 0.76
Biomarine extracts significantly protect from ultraviolet A-induced skin photoaging: an ex vivo study. Rejuvenation Res (2012) 0.76
The potential of class 3 semaphorins as both targets and therapeutics in cancer. Expert Opin Ther Targets (2014) 0.76
Herbo-probiotic therapy in cardioprotection: a new way of nature to nurture. Nutrition (2013) 0.75
Immune system and gut flora interactions are important episodes in metabolic diseases. J Gastrointestin Liver Dis (2012) 0.75
Corrigendum: Gs-coupled GPCR signalling in AgRP neurons triggers sustained increase in food intake. Nat Commun (2016) 0.75
A phytochemical approach to experimental metabolic syndrome-associated renal damage and oxidative stress. Rejuvenation Res (2012) 0.75
Isolation, structure, and functional elucidation of a modified pentapeptide, cysteine protease inhibitor (CPI-2081) from Streptomyces species 2081 that exhibit inhibitory effect on cancer cell migration. J Med Chem (2010) 0.75
Improving sperm quality and spermatogenesis through a bioactive marine compound: an experimental study. Acta Biomed (2012) 0.75
Anti-diabetic compounds and their patent information: an update. Recent Pat Inflamm Allergy Drug Discov (2013) 0.75
Status of research on matrix metalloproteinases (MMPs) in India. Expert Opin Ther Targets (2011) 0.75
Hepatoprotective potential of Cassia auriculata roots on ethanol and antitubercular drug-induced hepatotoxicity in experimental models. Pharm Biol (2014) 0.75